30 closest matches · ranked by relevance
Respiratory Syncytial Virus Infections · Chronic Lung Disease and <= 24 Months of Age or · Premature With Gestational Age <=35 Weeks and <=6 Months of Age
Primary: Number of Subjects Reporting Serious Adverse Events (SAEs) — 19; 7; 11 participants
Motavizumab Administration for a Second Season for RSV Prophylaxis
Primary: Number of Subjects Exhibiting Anti-motavizumab Antibodies — 2; 3; 0; 3 participants
Respiratory Syncytial Virus Infections
Primary: Incidence of RSV Hospitalization (Includes Deaths by RSV) — 62; 46 Participants
RSV Illness in ≤12 Months of Participants
Primary: Respiratory Syncytial Virus (RSV) Load in the Upper Respiratory Tract as Measured by Quantitative Real Time Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) at…
Healthy
Primary: Number of Participants With Respiratory Syncytial Virus (RSV) Hospitalization — 80; 21 Participants — p=<0.001
Respiratory Syncytial Virus Prophylaxis
Primary: Number of Subjects Reporting Adverse Events Through 30 Days After Dosing — 3; 5; 3; 6 Participants
Respiratory Syncytial Virus Infection · Premature Birth · Bronchopulmonary Dysplasia
Primary: Frequency of Adverse Events — 41 participants
Respiratory Syncytial Virus Infection
Primary: Number of Participants With Adverse Events — 99 Participants
Premature Infants
Primary: Number of Injections Per Patient Per Season — 3.8; 3.9; 4.0; 1.0 Injections administered
Respiratory Syncytial Virus Infection
Primary: Characterization of Participants With Risk Factors for Respiratory Syncytial Virus (RSV) Infection — 134; 449; 46; 160 participants
Respiratory Syncytial Virus Infection
Primary: Number of Hospital Admissions by Respiratory Syncytial Virus Infection — 2 participants
Respiratory Syncytial Virus (RSV)
Primary: Percentage of Participants With RSV Hospitalization — 0.0 percentage of participants
Respiratory Syncytial Virus Infections
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), Adverse Events of Special Interest (AESIs)…
RSV Immunization · Healthy Volunteer
Primary: Number of Participants With Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Infection (LRTI) Hospitalization Through the Respiratory Syncytial Virus Season…
Respiratory Syncytial Virus Infections
Primary: Part A: Serum Concentration of Suptavumab Over Time — 280; 177; 145; 128 mg/L
Respiratory Syncytial Virus (RSV)
Primary: Proportion of Infants Hospitalized for Lower Respiratory Tract Infection (LRTI) With a Positive Respiratory Syncytial Virus (RSV) Diagnostic Test — 1 participants
Respiratory Syncytial Virus Infections
Primary: Safety and Tolerability of MEDI8897 as Assessed by the Occurrence of All Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)…
RSV Infection
Primary: Number of Participants With Solicited Injection-site Adverse Events (AEs) in RSV Season 1 — 31; 32; 39; 54 Participants
Respiratory Syncytial Virus
Primary: Percentage of Participants Reporting Local Reactions Within 7 Days After Vaccination With RSVpreF or Placebo — 10.1; 6.5; 7.6; 11.5 Percentage of participants
Respiratory Syncytial Virus
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) — 17; 5; 31; 30 Participants
Respiratory Syncytial Virus Infections
Primary: PRNT (Subtype A) GMT — 300.5; 278.9; 311.9; 373.3 Titer
Bone Marrow Transplant Infection · Infection in Marrow Transplant Recipients · Respiratory Syncytial Virus Infections
Primary: Percentage of Participants With Progression to Lower Respiratory Tract Infection (LRI) — 8; 30; 10 percentage of participants
Respiratory Syncytial Virus Bronchiolitis
Primary: Percentage of Participants With Asthma at 6 Years of Age: Overall and by Prognostic Factor — 6.1; 11.2; 3.1; 9.6 percentage of participants
Respiratory Syncytial Virus Infection
Primary: RSV Season 1: Number of Participants With Respiratory Syncytial Virus (RSV)-Associated Medically Attended Lower Respiratory Infection (MALRI) — 60; 74 Participants…
Respiratory Viral Infections · Respiratory Syncytial Virus Infections · Parainfluenza Virus 3, Human
Primary: Number of Participants With Solicited Adverse Events (SEs) After Dose 1 — 12; 5; 8; 6 participants
Hematological Malignancies
Primary: Occurrences of Pneumonia — 4; 3 Participants
Respiratory Tract Infection
Primary: Percentage of Infant Participants With Medically Attended Lower Respiratory Tract Illness (MA-LRTI) Cases Due to RSV Occurring Within 90 Days After Birth (Efficacy)…
Respiratory Syncytial Virus Infection
Primary: Serum Palivizumab Trough Concentrations at Day 1, Day 31, and Day 121 — 0; 59.0; 91.8 µg/mL
Measles · Mumps · Rubella
Primary: Percentage of Participants Experiencing an Adverse Event (AE) After ProQuad® Dose 2 — 57.66 Percentage of Participants
RSV Infection
Primary: Number of Participants With Unsolicited Treatment Emergent Adverse Events (TEAEs) Through Day 151 — 1; 2; 3; 3 Participants